In Hong Kong on January 13, 2026, Akeso, Inc. (9926.HK) revealed findings from a real-world analysis at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The study compared the effectiveness of cadonilimab in combination with chemotherapy to that of a PD-1 inhibitor along with [include more information].